Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic’s ITB therapy demonstrates benefits for MS sufferers

Medtronic’s ITB therapy demonstrates benefits for MS sufferers

7th February 2011

Medtronic has highlighted a new study which illustrates the benefits its intrathecal baclofen (ITB) therapy can provide for multiple sclerosis (MS) patients affected by severe spasticity.

A paper published in Multiple Sclerosis Journal has collated more than 100 years worth of MS management experience to illustrate the proven clinical benefits ITB therapy can offer for those who are intolerant of oral spasticity therapies.

Medtronic ITB Therapy utilises the SynchroMed II pump to deliver baclofen injection directly to the intrathecal space, where it can then flow around the spinal cord.

However, the study showed that although the treatment has demonstrated effectiveness, it is currently utilised by only a small proportion of patients due to a lack of awareness among clinicians.

Tom Tefft, senior vice-president and president of the neuromodulation business at Medtronic, said: "This article is a very powerful analysis of the need for greater consideration of ITB therapy by clinicians who manage MS."

Last month, the firm introduced the CD Horizon Solera, a new fifth-generation spinal stabilisation system for those suffering from debilitating middle and lower back problems.ADNFCR-8000103-ID-800388989-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.